Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a report published on Monday, MarketBeat reports. The firm issued a buy rating and a $65.00 price target on the stock.

A number of other research firms also recently commented on JSPR. Oppenheimer restated an outperform rating and set a $80.00 price target on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Royal Bank of Canada initiated coverage on Jasper Therapeutics in a research report on Thursday, March 28th. They issued an outperform rating and a $70.00 target price for the company. TD Cowen assumed coverage on Jasper Therapeutics in a research report on Monday, March 18th. They set an outperform rating on the stock. Finally, Evercore ISI began coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an outperform rating and a $65.00 price objective for the company. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of Buy and an average price target of $64.29.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR traded down $2.08 during midday trading on Monday, hitting $22.44. 110,462 shares of the company's stock were exchanged, compared to its average volume of 114,543. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The firm has a market cap of $337.95 million, a P/E ratio of -3.55 and a beta of 2.25. The stock's 50 day moving average price is $25.43 and its 200-day moving average price is $14.82.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings results on Monday, March 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.65) by $0.15. On average, analysts expect that Jasper Therapeutics will post -5 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Velan Capital Investment Manag acquired 350,000 shares of the business's stock in a transaction on Thursday, February 8th. The shares were purchased at an average price of $12.95 per share, for a total transaction of $4,532,500.00. Following the acquisition, the insider now owns 1,188,500 shares in the company, valued at $15,391,075. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. purchased a new stake in shares of Jasper Therapeutics in the fourth quarter valued at $3,144,000. Kingdon Capital Management L.L.C. lifted its stake in Jasper Therapeutics by 16.4% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company's stock worth $2,793,000 after acquiring an additional 500,000 shares in the last quarter. Fernwood Investment Management LLC boosted its position in Jasper Therapeutics by 8.8% during the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company's stock worth $390,000 after acquiring an additional 40,000 shares during the period. Monaco Asset Management SAM purchased a new position in Jasper Therapeutics during the 4th quarter valued at about $197,000. Finally, Cowen AND Company LLC purchased a new stake in shares of Jasper Therapeutics in the third quarter worth approximately $140,000. Institutional investors and hedge funds own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.